Literature DB >> 25607236

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies.

Wenguang Chang1, Li Chen2, Grant M Hatch1,3.   

Abstract

The incidence of type 2 diabetes is increasing rapidly worldwide, and the development of novel anti-diabetic drugs is emerging. However, most anti-diabetic drugs cannot be used in patients with hepatic dysfunction, renal disease, and heart disease, which makes pharmacological therapy of type 2 diabetes complicated. Despite continued introduction of novel agents, the search for an ideal drug that is useful as both a hypoglycemic agent and to reduce diabetes-related complications remains elusive. Berberine is an isoquinoline alkaloid extract that has shown promise as a hypoglycemic agent in the management of diabetes in animal and human studies. Mechanistic studies have revealed beneficial effects of berberine on diabetes-related complications. Although there have been few clinical reports of the anti-diabetic effects of berberine, little documentation of adverse effects in humans positions it as a potential candidate drug to treat type 2 diabetes. In the present review, the anti-diabetic mechanism of berberine, its effect on diabetes-related complications, and its recent use in human clinical studies is highlighted. In addition, we summarize the different treatments for type 2 diabetes in adults and children.

Entities:  

Keywords:  adenosine-5′-monophosphate kinase; adults; berberine; berbérine; children; complications; diabète sucré de type 2; drug; enfants; hypoglycemic; hypoglycémiant; metabolism; médicament; métabolisme; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2014        PMID: 25607236     DOI: 10.1139/bcb-2014-0107

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  29 in total

1.  Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography.

Authors:  Peifeng Dai; Junhua Wang; Lin Lin; Yanyan Zhang; Zhengping Wang
Journal:  Exp Ther Med       Date:  2015-06-22       Impact factor: 2.447

Review 2.  Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes.

Authors:  Li Wen; Andrew Duffy
Journal:  J Nutr       Date:  2017-06-14       Impact factor: 4.798

3.  Berberine activates bitter taste responses of enteroendocrine STC-1 cells.

Authors:  Xiao Yue; Jie Liang; Fu Gu; Dongshu Du; Fuxue Chen
Journal:  Mol Cell Biochem       Date:  2018-01-23       Impact factor: 3.396

4.  Berberine Inhibits Oxygen Consumption Rate Independent of Alteration in Cardiolipin Levels in H9c2 Cells.

Authors:  Wenguang Chang; Ming Zhang; Li Chen; Grant M Hatch
Journal:  Lipids       Date:  2017-09-23       Impact factor: 1.880

5.  Berberine protects steatotic donor undergoing liver transplantation via inhibiting endoplasmic reticulum stress-mediated reticulophagy.

Authors:  Nan Zhang; Mingwei Sheng; Man Wu; Xinyue Zhang; Yijie Ding; Yuanbang Lin; Wenli Yu; Shusen Wang; Hongyin Du
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-25

6.  Berberine ameliorates diabetic neuropathic pain in a rat model: involvement of oxidative stress, inflammation, and μ-opioid receptors.

Authors:  Jun Dong; Zhongfu Zuo; Wei Yan; Wenqiang Liu; Qingyu Zheng; Xuezheng Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-12       Impact factor: 3.000

Review 7.  Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.

Authors:  Robert N Mahon; Richard Hafner
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

8.  Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203.

Authors:  He-Yi You; Xue-Meng Xie; Wei-Jian Zhang; Heng-Liang Zhu; Fei-Zhao Jiang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-05-03       Impact factor: 2.416

9.  Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis.

Authors:  Jianping Deng; Zicong Wu; Zhenling Zhao; Chaoxi Wu; Min Yuan; Zhengquan Su; Yifei Wang; Zhiping Wang
Journal:  Int J Nanomedicine       Date:  2020-06-03

10.  Prospecting the therapeutic edge of a novel compound (B12) over berberine in the selective targeting of Retinoid X Receptor in colon cancer.

Authors:  Temitayo I Subair; Opeyemi S Soremekun; Fisayo A Olotu; Mahmoud E S Soliman
Journal:  J Mol Model       Date:  2021-07-26       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.